June 28, Phase IIb Dog Cancer Interim Primary Endpoints Attained
210628_CanineInterimClinicalEndpoints
May 31, Top 20 Shareholders
210601_Top_Holders_Report – 2021-06-01T161455.048
May 14, Dr Kim Agnew Appointed PI of MPL Dog Cancer Trial
210514_DrKimAgnewAppointed for Dog Trial
April 30, Top 20 Shareholders
210501_Top_Holders_Report
April 29, Appendix 4C and Quarterly Update
210429_Appendix 4C and Quarterly Update
April 27, Monepantel Phase IIb Dog Lymphoma Interim Plasma Data
210427_PhaseIIb dose update therapeutic window
April 8, PharmAust Receives $750k R&D Tax Incentive Refund
210308_750K R&D TAX Return
April 7, LUMC: Monepantel Testing Indicates Anti-Covid19 Activity
210407_LUMC_Covid19_Testing
March 31, Top 20 Shareholders
210331_Top_Holders_Report – 2021-04-01T101952.158
March 31, Monepantel Phase IIb Dog Lymphoma Trial Update
210331_PhaseIIb Trial Update